The prognostic value of CINSARC in a randomised trial comparing histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001).

被引：0
|
作者：
Pasquali, Sandro
Braglia, Luca
Chibon, Frederic
Coindre, Jean Michel
Italiano, Antoine
Romagosa, Cleofe
Bague, Silvia
Dei Tos, Angelo Paolo
Palmerini, Emanuela
Quagliuolo, Vittorio
Broto, Javier Martin
Lopez-Pousa, Antonio
Grignani, Giovanni
Brunello, Antonella
Blay, Jean-Yves
Beveridge, Robert Diaz
Stacchiotti, Silvia
Merlo, Domenico F.
Casali, Paolo Giovanni
Gronchi, Alessandro
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy
[2] IRCCS Azienda Osped Univ San Martino, Ist Ist Nazl Ric Sul Canc, Clin Trial Ctr, Genoa, Italy
[3] IRCCS Azienda Osped Univ San Martino, Ist Ist Nazl Ric Sul Canc, Dept Epidemiol, Genoa, Italy
[4] Inst Bergonie, Bordeaux, France
[5] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[6] H Vall dHebron, Barcelona, Spain
[7] Hosp St Pau & Santa Creu, Pathol Dept, Barcelona, Spain
[8] Padua Univ Hosp, Padua, Italy
[9] IRCCS Ist Ortoped Rizzoli, Bologna, Italy
[10] Ist Clin Humanitas, Milan, Italy
[11] Univ Seville, Inst Biomed Res IBIS, CSIC, Virgen del Rocio Univ Hosp, Seville, Spain
[12] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[13] IRCCS, FPO, Candiolo Canc Inst, Div Med Oncol, Candiolo, TO, Italy
[14] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Med Oncol Unit 1, Padua, Italy
[15] Ctr Leon Berard, Unicanc, Lyon, France
[16] Med Oncol Dept, Valencia, Spain
[17] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[18] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Adult Mesenchymal & Rare Tumor Unit, Milan, Italy
[19] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Sarcoma Serv, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23531
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
    Gronchi, Alessandro
    Ferrari, Stefano
    Quagliuolo, Vittorio
    Martin-Broto, J.
    Lopez Pousa, Antonio
    Grignani, Giovanni
    Basso, Umberto
    Blay, Jean-Yves
    Tendero, Oscar
    Diaz Beveridge, Robert
    Ferraresi, Virginia
    Lugowska, Iwona
    Merlo, Domenico Franco
    Fontana, Valeria
    Marchesi, Emanuela
    Donati, Davide Maria
    Palassini, Elena
    Palmerini, Emanuela
    De Sanctis, Rita
    Morosi, Carlo
    Stacchiotti, Silvia
    Bague, Silvia
    Coindre, Jean Michelle
    Dei Tos, Angelo Paolo
    Picci, Piero
    Bruzzi, Paolo
    Casali, Paolo Giovanni
    LANCET ONCOLOGY, 2017, 18 (06): : 812 - 822
  • [2] Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (vol 18, pg 812, 2017)
    Gronchi, A.
    Ferrari, S.
    Quagliuolo, V
    LANCET ONCOLOGY, 2017, 18 (06): : E301 - E301
  • [3] CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
    Frezza, Anna Maria
    Stacchiotti, Silvia
    Chibon, Frederic
    Coindre, Jean-Michelle
    Italiano, Antoine
    Romagnosa, Cleofe
    Bague, Silvia
    Dei Tos, Angelo Paolo
    Braglia, Luca
    Palmerini, Emanuela
    Quagliuolo, Vittorio
    Broto, Javier Martin
    Pousa, Antonio Lopez
    Grignani, Giovanni
    Brunello, Antonella
    Blay, Jean-Yves
    Beveridge, Robert Diaz
    Lugowska, Iwona
    Lesluyes, Tom
    Maestro, Roberta
    Merlo, Franco Domenico
    Casali, Paolo Giovanni
    Gronchi, Alessandro
    CANCER MEDICINE, 2023, 12 (02): : 1350 - 1357
  • [4] Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial
    Vanzulli, A.
    Vigorito, R.
    Buonomenna, C.
    Palmerini, E.
    Quagliuolo, V.
    Broto, J. M.
    Pousa, A. Lopez
    Grignani, G.
    Brunello, A.
    Blay, J. -y.
    Beveridge, R. Diaz
    Ferraresi, V.
    Lugowska, I.
    Pizzamiglio, S.
    Verderio, P.
    Duroni, V.
    Fontana, V.
    Donati, D. M.
    Palassini, E.
    Bianchi, G.
    Bertuzzi, A.
    Buonadonna, A.
    Pasquali, S.
    Tos, A. P. Dei
    Casali, P. G.
    Morosi, C.
    Stacchiotti, S.
    Gronchi, A.
    ESMO OPEN, 2025, 10 (03)
  • [5] Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial
    Pasquali, Sandro
    Palmerini, Emanuela
    Quagliuolo, Vittorio
    Martin-Broto, Javier
    Lopez-Pousa, Antonio
    Grignani, Giovanni
    Brunello, Antonella
    Blay, Jean-Yves
    Tendero, Oscar
    Diaz-Beveridge, Robert
    Ferraresi, Virginia
    Lugowska, Iwona
    Infante, Gabriele
    Braglia, Luca
    Merlo, Domenico Franco
    Fontana, Valeria
    Marchesi, Emanuela
    Donati, Davide Maria
    Palassini, Elena
    Bianchi, Giuseppe
    Marrari, Andrea
    Morosi, Carlo
    Stacchiotti, Silvia
    Bague, Silvia
    Coindre, Jean Michel
    Dei Tos, Angelo Paolo
    Picci, Piero
    Bruzzi, Paolo
    Miceli, Rosalba
    Casali, Paolo Giovanni
    Gronchi, Alessandro
    CANCER, 2022, 128 (01) : 85 - 93
  • [6] Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial (vol 8, pg 85, 2022)
    Pasquali, S.
    Palmerini, E.
    Quagliuolo, V
    CANCER, 2022, 128 (17) : 3265 - 3265
  • [7] Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial
    Pasquali, Sandro
    Collini, Paola
    Romagosa, Cleofe
    Coindre, Jean Michel
    Pizzamiglio, Sara
    Verderio, Paolo
    Barisella, Marta
    Palmerini, Emanuela
    Quagliuolo, Vittorio
    Broto, Javier Martin
    Lopez-Pousa, Antonio
    Grignani, Giovanni
    Blay, Jean-Yves
    Lugowska, Iwona A.
    Fontana, Valeria
    Sbaraglia, Marta
    Bague, Silvia
    De Tos, Paolo
    Casali, Paolo G.
    Gronchi, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy
    Palassini, Elena
    Pizzamiglio, Sara
    Palmerini, Emanuela
    Quagliuolo, Vittorio
    Broto, Javier Martin
    Grignani, Giovanni
    Brunello, Antonella
    Blay, Jean-Yves
    Tendero, Oscar
    Beveridge, Robbie
    Pousa, Antonio Lopez
    Ferraresi, Virginia
    Lugowska, Iwona
    Fontana, Valeria
    Bianchi, Giuseppe
    Stacchiotti, Silvia
    Dei Tos, Angelo Paolo
    Verderio, Paolo
    Casali, Paolo Giovanni
    Gronchi, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Indication for neoadjuvant chemotherapy in adult patients with high-risk soft-tissue sarcomas.
    Kasper, B.
    Kuehl, E.
    Wuchter, P.
    Bernd, L.
    Ho, A. D.
    Egerer, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 539S - 539S
  • [10] Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
    Martin-Broto, Javier
    Lopez-Alvarez, Maria
    Moura, David S.
    Ramos, Rafael
    Collini, Paola
    Romagosa, Cleofe
    Bague, Silvia
    Renne, Salvatore L.
    Barisella, Marta
    Velasco, Valerie
    Coindre, Jean-Michel
    Lopez-Lopez, Daniel
    Dopazo, Joaquin
    Gambarotti, Marco
    Braglia, Luca
    Merlo, Domenico Franco
    Palmerini, Emanuela
    Stacchiotti, Silvia
    Quagliuolo, Vittorio L.
    Lopez-Pousa, Antonio
    Grignani, Giovanni
    Blay, Jean-Yves
    Brunello, Antonella
    Gutierrez, Antonio
    Valverde, Claudia
    Hindi, Nadia
    Dei Tos, Angelo Paolo
    Picci, Piero
    Casali, Paolo G.
    Gronchi, Alessandro
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12) : 2539 - 2552
12345